Seminars in Thoracic and Cardiovascular Surgery
Volume 20, Issue 2 , Pages 87-93 , Summer 2008

Paracrine Effects of Cell Transplantation: Modifying Ventricular Remodeling in the Failing Heart

  • Paul W.M. Fedak, MD, PhD, FRCSC

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Paul W. M. Fedak, MD, PhD, FRCSC, Foothills Medical Center, C803, 1403-29 St. N.W., Calgary, Alberta, Canada, T2N 2T9

References 

  1. Murry CE, Field LJ, Menasche P. Cell-based cardiac repair: reflections at the 10-year point. Circulation. 2005;112:3174–3183
  2. Menasche P. Cellular transplantation: hurdles remaining before widespread clinical use. Curr Opin Cardiol. 2004;19:154–161
  3. Li RK, Jia ZQ, Weisel RD, et al. Cardiomyocyte transplantation improves heart function. Ann Thorac Surg. 1996;62:654–660discussion 660-651
  4. Fedak PW, Weisel RD, Verma S, et al. Restoration and regeneration of failing myocardium with cell transplantation and tissue engineering. Semin Thorac Cardiovasc Surg. 2003;15:277–286
  5. Tang GH, Fedak PW, Yau TM, et al. Cell transplantation to improve ventricular function in the failing heart. Eur J Cardio-Thorac Surg. 2003;23:907–916
  6. Li RK, Weisel RD, Mickle DA, et al. Autologous porcine heart cell transplantation improved heart function after a myocardial infarction. J Thorac Cardiovasc Surg. 2000;119:62–68
  7. Tomita S, Li RK, Weisel RD, et al. Autologous transplantation of bone marrow cells improves damaged heart function. Circulation. 1999;100(suppl 19):II247–II256
  8. Tomita S, Mickle DA, Weisel RD, et al. Improved heart function with myogenesis and angiogenesis after autologous porcine bone marrow stromal cell transplantation. J Thorac Cardiovasc Surg. 2002;123:1132–1140
  9. Menasche P, Hagege AA, Scorsin M, et al. Myoblast transplantation for heart failure. Lancet. 2001;357:279–280
  10. Menasché P, Alfieri O, Janssens S, et al. The Myoblast Autologous Grafting in Ischemic Cardiomyopathy (MAGIC) trial: first randomized placebo-controlled study of myoblast transplantation. Circulation. 2008;117:1189–1200
  11. Fedak PW, Verma S, Weisel RD, et al. Cardiac remodeling and failure from molecules to man (Part II). Cardiovasc Pathol. 2005;14:49–60
  12. Fedak PW, Verma S, Weisel RD, et al. Cardiac remodeling and failure: from molecules to man (Part I). Cardiovasc Pathol. 2005;14:1–11
  13. Reinecke H, Murry CE. Taking the death toll after cardiomyocyte grafting: a reminder of the importance of quantitative biology. J Mol Cell Cardiol. 2002;34:251–253
  14. Fedak PW, Verma S, Weisel RD, et al. Angiogenesis: protein, gene, or cell therapy?. Heart Surg Forum. 2001;4:301–304
  15. Szmitko PE, Fedak PW, Weisel RD, et al. Endothelial progenitor cells: new hope for a broken heart. Circulation. 2003;107:3093–3100
  16. Formigli L, Perna AM, Meacci E, et al. Paracrine effects of transplanted myoblasts and relaxin on post-infarction heart remodeling. J Cell Mol Med. 2007;11:1087–1100
  17. Nanjundappa A, Raza JA, Dieter RS, et al. Cell transplantation for treatment of left-ventricular dysfunction due to ischemic heart failure: from bench to bedside. Expert Rev Cardiovasc Ther. 2007;5:125–131
  18. Payne TR, Oshima H, Okada M, et al. A relationship between vascular endothelial growth factor, angiogenesis, and cardiac repair after muscle stem cell transplantation into ischemic hearts. J Am Coll Cardiol. 2007;50:1677–1684
  19. Tse HF, Siu CW, Zhu SG, et al. Paracrine effects of direct intramyocardial implantation of bone marrow derived cells to enhance neovascularization in chronic ischemic myocardium. Eur J Heart Fail. 2007;9:747–753
  20. Nomi M, Miyake H, Sugita Y, et al. Role of growth factors and endothelial cells in therapeutic angiogenesis and tissue engineering. Curr Stem Cell Res Ther. 2006;1:333–343
  21. Yau TM, Li G, Zhang Y, et al. Vascular endothelial growth factor receptor upregulation in response to cell-based angiogenic gene therapy. AnnThorac Surg. 2005;79:2056–2063
  22. Liu TB, Fedak PW, Weisel RD, et al. Enhanced IGF-1 expression improves smooth muscle cell engraftment after cell transplantation. Am J Physiol Heart Circ Physiol. 2004;287:H2840–H2849
  23. Kim C, Li RK, Li G, et al. Effects of cell-based angiogenic gene therapy at 6 months: persistent angiogenesis and absence of oncogenicity. Ann Thorac Surg. 2007;83:640–646
  24. Yau TM, Kim C, Li G, et al. Enhanced angiogenesis with multimodal cell-based gene therapy. Ann Thorac Surg. 2007;83:1110–1119
  25. Yau TM, Kim C, Li G, et al. Maximizing ventricular function with multimodal cell-based gene therapy. Circulation. 2005;112(suppl 9):I123–I128
  26. Fedak PW, Szmitko PE, Weisel RD, et al. Cell transplantation preserves matrix homeostasis: a novel paracrine mechanism. J Thorac Cardiovasc Surg. 2005;130:1430–1439
  27. Ohno N, Fedak PW, Weisel RD, et al. Cell transplantation in non-ischemic dilated cardiomyopathy (A novel biological approach for ventricular restoration). Jpn J Thorac Cardiovasc Surg. 2002;50:457–460
  28. Ohno N, Fedak PW, Weisel RD, et al. Transplantation of cryopreserved muscle cells in dilated cardiomyopathy: effects on left ventricular geometry and function. J Thorac Cardiovasc Surg. 2003;126:1537–1548
  29. Yoo KJ, Li RK, Weisel RD, et al. Autologous smooth muscle cell transplantation improved heart function in dilated cardiomyopathy. Ann Thorac Surg. 2000;70:859–865
  30. Scorsin M, Hagege AA, Dolizy I, et al. Can cellular transplantation improve function in doxorubicin-induced heart failure?. Circulation. 1998;98(suppl 19):II151–II155discussion II155-II156
  31. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007;87:1285–1342
  32. Baicu CF, Stroud JD, Livesay VA, et al. Changes in extracellular collagen matrix alter myocardial systolic performance. Am J Physiol Heart Circ Physiol. 2003;284:H122–H132
  33. Anand IS, Liu D, Chugh SS, et al. Isolated myocyte contractile function is normal in postinfarct remodeled rat heart with systolic dysfunction. Circulation. 1997;96:3974–3984
  34. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003;92:827–839
  35. Fedak PW, Altamentova SM, Weisel RD, et al. Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. Am J Physiol Heart Circ Physiol. 2003;284:H626–H634
  36. Murtuza B, Suzuki K, Bou-Gharios G, et al. Transplantation of skeletal myoblasts secreting an IL-1 inhibitor modulates adverse remodeling in infarcted murine myocardium. Proc Natl Acad Sci USA. 2004;101:4216–4221
  37. Uemura R, Xu M, Ahmad N, et al. Bone marrow stem cells prevent left ventricular remodeling of ischemic heart through paracrine signaling. Circ Res. 2006;98:1414–1421
  38. Gnecchi M, He H, Liang OD, et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med. 2005;11:367–368
  39. Kinnaird T, Stabile E, Burnett MS, et al. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation. 2004;109:1543–1549
  40. Kinnaird T, Stabile E, Burnett MS, et al. Marrow derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res. 2004;94:678–685
  41. Singla DK, Lyons GE, Kamp TJ. Transplanted embryonic stem cells following mouse myocardial infarction inhibit apoptosis and cardiac remodeling. Am J Physiol Heart Circ Physiol. 2007;293:H1308–H1314
  42. Singla DK, McDonald DE. Factors released from embryonic stem cells inhibit apoptosis of H9c2 cells. Am J Physiol Heart Circ Physiol. 2007;293:H1590–H1595
  43. Fazel S, Chen L, Weisel RD, et al. Cell transplantation preserves cardiac function after infarction by infarct stabilization: augmentation by stem cell factor. J Thorac Cardiovasc Surg. 2005;130:1310
  44. Fazel S, Cimini M, Chen L, et al. Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest. 2006;116:1865–1877
  45. Ott HC, Matthiesen TS, Goh SK, et al. Perfusiondecellularized matrix: using nature's platform to engineer a bioartificial heart. Nat Med. 2008;14:213–221
  46. Barile L, Messina E, Giacomello A, et al. Endogenous cardiac stem cells. Prog Cardiovasc Dis. 2007;50:31–48
  47. Smith RR, Barile L, Cho HC, et al. Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation. 2007;115:896–908
  48. Fedak PWM, Weisel RD, Li RK. Cell transplantation for cardiovascular disease. In:  Sellke F,  Swanson S,  del Nido P editor. Sabiston and Spencer Surgery of the Chest. Philadelphia: Elsevier Saunders; 2004;p. 1719

 PWMF is a clinical investigator of the Alberta Heritage Foundation for Medical Research.

PII: S1043-0679(08)00068-3

doi: 10.1053/j.semtcvs.2008.04.001

Seminars in Thoracic and Cardiovascular Surgery
Volume 20, Issue 2 , Pages 87-93 , Summer 2008

Article Tools

* Image Usage & Resolution